A role for orexin in cytotoxic chemotherapy-induced fatigue

Brain, Behavior, and Immunity

Volumn 37, Issue , 2014, Pages 84-94

  Weymann, K B ^a   Wood, L J ^a,b   Zhu, X ^a   Marks, D L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

Author keywords

Activity; Cancer treatment; Cytotoxic chemotherapy; Fatigue; Hypothalamus; Inflammation; Orexin; Sickness behavior; Wakefulness

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OREXIN A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID LEVEL; CHEMOTHERAPY INDUCED FATIGUE; ENCEPHALITIS; FATIGUE; GENE EXPRESSION; HYPOTHALAMUS; INFLAMMATION; LOCOMOTION; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TELEMETRY;

ACTIVITY; CANCER TREATMENT; CYTOTOXIC CHEMOTHERAPY; FATIGUE; HYPOTHALAMUS; INFLAMMATION; OREXIN; SICKNESS BEHAVIOR; WAKEFULNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN STEM; CYCLOPHOSPHAMIDE; CYTOTOXINS; DOXORUBICIN; DRUG COMBINATIONS; ENCEPHALITIS; FATIGUE; FEMALE; FLUOROURACIL; GENE EXPRESSION; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURONS; NEUROPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896730953     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.11.003     Document Type: Article

References (82)

1. Anaclet C., Parmentier R., Ouk K., Guidon G., Buda C., Sastre J.P., Akaoka H., Sergeeva O.A., Yanagisawa M., Ohtsu H., Franco P., Haas H.L., Lin J.S. Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J. Neurosci. 2009, 29:14423-14438.
2. Baumann C.R., Stocker R., Imhof H.G., Trentz O., Hersberger M., Mignot E., Bassetti C.L. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005, 65:147-149.
3. Berger A.M., Gerber L.H., Mayer D.K. Cancer-related fatigue: implications for breast cancer survivors. Cancer 2012, 118:2261-2269.
4. Bluthe R.M., Michaud B., Kelley K.W., Dantzer R. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 1996, 7:2823-2827.
5. Bluthe R.M., Walter V., Parnet P., Laye S., Lestage J., Verrier D., Poole S., Stenning B.E., Kelley K.W., Dantzer R. Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C. R. l'Academie. Sci. 1994, 317:499-503.
6. Bower J.E., Lamkin D.M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 2013, (Suppl. S48-57).
7. Briones T.L., Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci. 2011, 12:124.
8. Bruera E., Yennurajalingam S., Palmer J.L., Perez-Cruz P.E., Frisbee-Hume S., Allo J.A., Williams J.L., Cohen M.Z. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J. Clin. Oncol. 2013, 31:2421-2427.
9. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
10. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130:226-238.
11. Carter M.E., Brill J., Bonnavion P., Huguenard J.R., Huerta R., de Lecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2635-2644.
12. Carter M.E., de Lecea L., Adamantidis A. Functional wiring of hypocretin and LC-NE neurons: implications for arousal. Front. Behav. Neurosci. 2013, 7:43.
13. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
14. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Lee B.N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97:2919-2925.
15. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., Johnson D.H., Miaskowski C., Scherr S.L., Portenoy R.K., Vogelzang N.J. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000, 5:353-360.
16. Dantzer R., Capuron L., Irwin M.R., Miller A.H., Ollat H., Perry V.H., Rousey S., Yirmiya R. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008, 33:18-29.
17. Dantzer R., Meagher M.W., Cleeland C.S. Translational approaches to treatment-induced symptoms in cancer patients. Natl. Rev. Clin. Oncol. 2012, 9:414-426.
18. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:748-753.
19. de Jong N., Candel M.J., Schouten H.C., Abu-Saad H.H., Courtens A.M. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann. Oncol. 2004, 15:896-905.
20. Desarnaud F., Murillo-Rodriguez E., Lin L., Xu M., Gerashchenko D., Shiromani S.N., Nishino S., Mignot E., Shiromani P.J. The diurnal rhythm of hypocretin in young and old F344 rats. Sleep 2004, 27:851-856.
21. Elsea C.R., Roberts D.A., Druker B.J., Wood L.J. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PloS One 2008, 3:e2355.
22. Estabrooke I.V., McCarthy M.T., Ko E., Chou T.C., Chemelli R.M., Yanagisawa M., Saper C.B., Scammell T.E. Fos expression in orexin neurons varies with behavioral state. J. Neurosci. 2001, 21:1656-1662.
23. Fardell J.E., Vardy J., Shah J.D., Johnston I.N. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berlin) 2012, 220:183-193.
24. Fenzl T., Romanowski C.P., Flachskamm C., Deussing J.M., Kimura M. Wake-promoting effects of orexin: its independent actions against the background of an impaired corticotropine-releasing hormone receptor system. Behav. Brain Res. 2011, 222:43-50.
25. Furutani N., Hondo M., Kageyama H., Tsujino N., Mieda M., Yanagisawa M., Shioda S., Sakurai T. Neurotensin co-expressed in orexin-producing neurons in the lateral hypothalamus plays an important role in regulation of sleep/wakefulness states. PloS One 2013, 8:e62391.
26. Gaykema R.P., Goehler L.E. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain Behav. Immun. 2009, 23:926-930.
27. Gaykema R.P., Goehler L.E. Ascending caudal medullary catecholamine pathways drive sickness-induced deficits in exploratory behavior: brain substrates for fatigue?. Brain Behav. Immun. 2011, 25:443-460.
28. Gayle D., Ilyin S.E., Flynn M.C., Plata-Salaman C.R. Lipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAs. Brain Res. 1998, 795:77-86.
29. Gerashchenko D., Kohls M.D., Greco M., Waleh N.S., Salin-Pascual R., Kilduff T.S., Lappi D.A., Shiromani P.J. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J. Neurosci. 2001, 21:7273-7283.
30. Gerashchenko D., Murillo-Rodriguez E., Lin L., Xu M., Hallett L., Nishino S., Mignot E., Shiromani P.J. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp. Neurol. 2003, 184:1010-1016.
31. Gerashchenko D., Shiromani P.J. Effects of inflammation produced by chronic lipopolysaccharide administration on the survival of hypocretin neurons and sleep. Brain Res. 2004, 1019:162-169.
32. Grossberg A.J., Zhu X., Leinninger G.M., Levasseur P.R., Braun T.P., Myers M.G., Marks D.L. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J. Neurosci. 2011, 31:11376-11386.
33. Harris G.C., Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006, 29:571-577.
34. Jean-Pierre P., Morrow G.R., Roscoe J.A., Heckler C., Mohile S., Janelsins M., Peppone L., Hemstad A., Esparaz B.T., Hopkins J.O. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010, 116:3513-3520.
35. Kantor S., Mochizuki T., Lops S.N., Ko B., Clain E., Clark E., Yamamoto M., Scammell T.E. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 2013, 36:1129-1138.
36. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17(Suppl. 1):S112-118.
37. Kiwaki K., Kotz C.M., Wang C., Lanningham-Foster L., Levine J.A. Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E551-559.
38. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002, 25:154-159.
39. Kotz C.M., Teske J.A., Levine J.A., Wang C. Feeding and activity induced by orexin A in the lateral hypothalamus in rats. Regul. Pept. 2002, 104:27-32.
40. Kummer F., Catuogno S., Perseus J.M., Bloch W., Baumann F.T. Relationship between cancer-related fatigue and physical activity in inpatient cancer rehabilitation. Anticancer Res. 2013, 33:3415-3422.
41. Lee M.G., Hassani O.K., Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 2005, 25:6716-6720.
42. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
43. Little, K., 2007. A Rat Model of Sytemic Chemotherapy for Breast Cancer to Evaluate and Treat Chemobrain. <>. http://www.researchgate.net/publication/235098916.
44. Liu L., Mills P.J., Rissling M., Fiorentino L., Natarajan L., Dimsdale J.E., Sadler G.R., Parker B.A., Ancoli-Israel S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav. Immun. 2012, 26:706-713.
45. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, CA) 2001, 25:402-408.
46. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. 2003, 3:330-338.
47. Lower E.E., Fleishman S., Cooper A., Zeldis J., Faleck H., Yu Z., Manning D. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J. Pain Symptom Manage. 2009, 38:650-662.
48. Mahoney S.E., Davis J.M., Murphy E.A., McClellan J.L., Gordon B., Pena M.M. Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1. Brain Behav. Immun. 2013, 27:155-161.
49. McNeely M.L., Courneya K.S. Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J. Natl. Compr. Canc. Netw. 2010, 8:945-953.
50. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
51. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P.C. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J. Pain Symptom Manage. 2011, 41:761-767.
52. Mitchell S.A., Beck S.L., Hood L.E., Moore K., Tanner E.R. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin. J. Oncol. Nurs. 2007, 11:99-113.
53. Nakamura T., Uramura K., Nambu T., Yada T., Goto K., Yanagisawa M., Sakurai T. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000, 873:181-187.
54. Nollet M., Gaillard P., Minier F., Tanti A., Belzung C., Leman S. Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 2011, 61:336-346.
55. Novak C.M., Levine J.A. Daily intraparaventricular orexin-A treatment induces weight loss in rats. Obesity (Silver Spring, Md) 2009, 17:1493-1498.
56. Paxinos G., Franklin K. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York.
57. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
58. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
59. Ray M.A., Trammell R.A., Verhulst S., Ran S., Toth L.A. Development of a mouse model for assessing fatigue during chemotherapy. Comp. Med. 2011, 61:119-130.
60. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. Faseb J. 2007, 22:659-661.
61. Reilly C.M., Bruner D.W., Mitchell S.A., Minasian L.M., Basch E., Dueck A.C., Cella D., Reeve B.B. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support. Care Cancer 2013, 21:1525-1550.
62. Ryan J.L., Carroll J.K., Ryan E.P., Mustian K.M., Fiscella K., Morrow G.R. Mechanisms of cancer-related fatigue. Oncologist 2007, 12(Suppl. 1):22-34.
63. Saligan L.N., Kim H.S. A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav. Immun. 2012, 26:830-848.
64. Samson W.K., Bagley S.L., Ferguson A.V., White M.M. Orexin receptor subtype activation and locomotor behaviour in the rat. Acta Physiol. 2010, 198:313-324. (Oxford, England).
65. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
66. Sauter K.A., Wood L.J., Wong J., Iordanov M., Magun B.E. Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. Cancer Biol. Ther. 2011, 11:1008-1016.
67. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
68. Schwartz A.L., Nail L.M., Chen S., Meek P., Barsevick A.M., King M.E., Jones L.S. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000, 18:11-19.
69. Scott J.A., Lasch K.E., Barsevick A.M., Piault-Louis E. Patients' experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol. Nurs. Forum 2011, 38:E191-203.
70. Shi Q., Smith T.G., Michonski J.D., Stein K.D., Kaw C., Cleeland C.S. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer 2011, 117:2779-2790.
71. Smalley R.V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res. Treat. 1983, 3:209-220.
72. Spelten E.R., Verbeek J.H., Uitterhoeve A.L., Ansink A.C., van der Lelie J., de Reijke T.M., Kammeijer M., de Haes J.C., Sprangers M.A. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur. J. Cancer 2003, 39:1562-1567.
73. Takahashi K., Lin J.S., Sakai K. Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience 2008, 153:860-870.
74. Vacchelli E., Galluzzi L., Fridman W.H., Galon J., Sautes-Fridman C., Tartour E., Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012, 1:179-188.
75. Wenzel J.A., Griffith K.A., Shang J., Thompson C.B., Hedlin H., Stewart K.J., DeWeese T., Mock V. Impact of a home-based walking intervention on outcomes of sleep quality, emotional distress, and fatigue in patients undergoing treatment for solid tumors. Oncologist 2013, 18:476-484.
76. Willie J.T., Lim M.M., Bennett R.E., Azarion A.A., Schwetye K.E., Brody D.L. Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice. J. Neurotrauma 2012, 29:1908-1921.
77. Wong J., Smith L.B., Magun E.A., Engstrom T., Kelley-Howard K., Jandhyala D.M., Thorpe C.M., Magun B.E., Wood L.J. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol. Ther. 2012, 14:56-63.
78. Wood L.J., Nail L.M., Perrin N.A., Elsea C.R., Fischer A., Druker B.J. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol. Res. Nurs. 2006, 8:157-169.
79. Wood L.J., Weymann K. Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr. Opin. Support. Palliat. Care 2013, 7:54-59.
80. Wu M.F., John J., Maidment N., Lam H.A., Siegel J.M. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am. J. Physiol. 2002, 283:R1079-1086.
81. Yamanaka A., Tabuchi S., Tsunematsu T., Fukazawa Y., Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J. Neurosci. 2010, 30:12642-12652.
82. Yoshida K., McCormack S., Espana R.A., Crocker A., Scammell T.E. Afferents to the orexin neurons of the rat brain. J. Comp. Neurol. 2006, 494:845-861.